Kornimate/medical-research-clean huggingface dataset:
relationship between dysphonia and anxiety in fibromyalgia

Conditions: Dysphonia; Fibromyalgia; Anxiety Disorders

Summary: our aim in conducting this study is to determine the relationship between voice disorders and anxiety in patients with fibromyalgia syndrome (fs).

this case controlled study was performed at the physical medicine and rehabilitation outpatient clinic between april 2022 and june 2022. 25 patients who were diagnosed with fs according to the 2010 american college of rheumatology (acr) criteria were included in the study. for the control group 25 healthy volunteers with no previous chronic disease history were included . the investigators planed to investigate the relationship between the anxiety level of the fs patients and dysphonia. thus an acoustic voice analysis (fundamental frequency (f0), jitter, shimmer, noise to harmonic ratio (nhr), harmonic to noise ratio (hnr)) and an aerodynamic analysis (maximal phonation time (mpt)) were performed by an experienced otolaryngologist specialized in voice disorders for evaluation of objective voice quality and function. these analyses were performed on all the volunteers from both groups, and the results obtained were compared between the groups.

Eligibility criteria:
inclusion criteria: * diagnosed with fibromyalgia syndrome for at least 1 year * minimum vas score of 3 exclusion criteria: * patients with diabetes mellitus, * other rheumatological diseases, * malignancies, * connective tissue disorders * neuromuscular diseases and * hereditary diseases.

Keywords: anxiety fibromyalgia dysphonia
effects of a single chemotherapy administration on skeletal muscle of breast cancer patients: comparison of paclitaxel vs paclitaxel + trastuzumab vs paclitaxel + carboplatine: the protect-06 bis study

Conditions: Breast Cancer

Summary: this study aims to investigate the acute effects (i.e. 4 days) of paclitaxel or paclitaxel vs trastuzumab or paclitaxel and carboplatine on skeletal muscle of breast cancer patients. muscle biopsies will be performed, as well as measurements of body composition strength, muscle architecture and quality of life.

breast cancer patients are commonly treated with chemotherapy, which is known to induce severe side effects such as skeletal muscle deconditioning, characterized by skeletal muscle atrophy and major mitochondrial alterations. these maladaptations, observed in patients treated with epirubicin-cyclophosphamide (ec) followed by weekly paclitaxel (tax), ultimately lead to reduction in exercise capacity and quality of life. however, little is known about the specific effect of each type of chemotherapy. in our recent article (see citations field in the references module), the investigators demonstrated that chemotherapy effects on skeletal muscle are drug-dependent. using muscle biopsies before and 4 days after the first administration of ec or tax, we demonstrated that unlike tax, ec induced severe muscle atrophy and mitochondrial alterations. of note, patients in the tax group had already received ec during the preceding weeks (figure 1). therefore, these patients had already begun to have altered skeletal muscle homeostasis, which might have limited the influence of tax compared with that of its administration in isolation (i.e., without other previous chemotherapy administrations). in addition, some patients had received, concomitantly with tax, trastuzumab (trastu) due to her tumor mutation. also, in triple negative breast cancers, the recommendations concerning neo(adjuvant) chemotherapy have recently changed and recommend starting treatment with the use of paclitaxel + carboplatin (tax + carbo).

Eligibility criteria:
inclusion criteria: tax group : * female ≥ 18 years * stage i to iii breast cancer * patient who has not yet started treatment with tax * enrolled in a social security scheme * able to speak, read and understand french tax+trastu group : * female ≥ 18 years of age * stage i to iii breast cancer * patient who has not yet started treatment with tax+trastu (tolaney regimen) * enrolled in a social security scheme * able to speak, read and understand french exclusion criteria: * prior exposure to chemotherapy * musculoskeletal disorders, autoimmune, vascular or neuromuscular disease * implantation of a pacemaker * contraindications to fitness evaluation * contraindication to local anesthesia for microbiopsy * minor or protected adult * pregnant women

Keywords: protein turnover skeletal muscle deconditoning breast cancer chemotherapy muscle biopsy
multivariate analysis and machine learning model risk prediction of recurrent pain after plif surgery for degenerative lumbar spine disease at long-term follow-up

Conditions: Lumbar Disc Herniation; Lumbar Degenerative Disease; Sarcopenia

Summary: the study was a clinical retrospective study designed to investigate risk factors for long-term recurrent pain after plif in patients with lumbar degenerative disease and to improve patient outcomes


Eligibility criteria:
inclusion criteria: 1. confirmed diagnosis of lumbar degenerative disease (spinal stenosis, disc herniation with lumbar instability, and lumbar spondylolisthesis), with no significant symptomatic relief after conservative treatment for more than 3 months, and in need of surgical intervention; 2. lumbar spinal fusion surgical treatment with plif; 3. grouping based on the presence or absence of a lumbar or limb pain with vas ≥3 at the 12-18 month postoperative follow-up; 4. observational indicators including individual factors, surgical factors, spine-pelvis sagittal balance parameters, and paravertebral muscle parameters. exclusion criteria: (1) those with a history of lumbar spine trauma, inflammation, tumor, or surgery; (2) those with congenital or acquired severe lumbar vertebral deformity; (3) those with severe neurological dysfunction; (4) those with incomplete baseline and follow-up data.

Keywords: lumbar degenerative disease plif sarcopenia sagittal balance machine learning svm cross validation
evaluating the safety of the spectralis centaurus device

Conditions: Retinal Diseases

Summary: the objective of this clinical trial is to evaluate the safety of the spectralis centaurus device (huce-optolab, bfh ti, biel, ch) in a clinical setting on patients with retinal diseases.

optical microsurgery of the retinal pigment epithelium (rpe) requires reliable real-time dosimetry to prevent unwanted overexposure of the neuroretina. the spectralis centaurus device implements optical coherence tomography (oct) to detect intentional elimination of rpe cells caused by a prototype laser for selective retina therapy (srt). within this clinical trial the safety of the spectralis centaurus device and its ability to detect rpe cell damage towards selective real-time laser microsurgery will be evaluated.

Eligibility criteria:
inclusion criteria: * written informed consent * for stage 1, any patient aged \>18 years with the need for conventional laser retina ablation * for stage 2, will be restricted to people aged 50 to \<95 years with lesion characteristics that meet the criteria for intermediate amd exclusion criteria: * presence of reticular pseudodrusen * any manifestation of late-stage amd * known hypersensitivity or allergy to fluorescein or uncontrolled hypertension * concomitant systemic corticosteroid treatment for continuous period longer than 2 weeks * history of any vitreous haemorrhage within 4 weeks prior to screening or current haemorrhage in the study eye * inability to obtain fundus photographs or fluorescein angiogram of sufficient quality * photosensitive epilepsy * insufficient retinal pigmentation (albinism) * corneal opacity / lens opacity * women of child-bearing potential * contralateral eye is at an advanced stage of disease and has poor visual acuity * inability to follow the procedures of the study * participation in another study with investigational drug within the 30 days preceding and during the present study - inability or lack of willingness to commit to return for all clinical visits and complete all study-related procedures

Keywords: retinal pigment epithelium
the value of using colostrum supplements on the physical performance and cognitive function in healthy subjects and type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: the goal of this interventional randomized clinical is to compare the effect of colostrum pharmaceutical preparation and placebo in a sample of iraqi participants. the main questions to answer are: 1. what are the effects of the tested regimens on the level of il-1 and il-15. 2. what are the effects of the tested regimens on the fasting blood glucose? 3. what are the effects of the tested regimens on the hba1c? 4. what are the effects of the tested regimens on the body mass index? 5. what are the effects of the tested regimens on the lipid profile? 6. what are the effects of the tested regimens on c-reactive protein? 7. what are the effects of the tested regimens on hematological indices? 8. what are the effects of the tested regimens on rate pressure product? participants will be separated into four groups: 1. group 1 (healthy control): 24 patients, will be receiving placebo capsule per oral once daily for 60 days 2. group 2 (healthy control) : 26 patients, will be receiving colostrum capsule 500 mg per oral once daily. 3. group 3 (diabetes type 2): 23 pateins, will be receiving placebo capsule per oral once daily for 60 days 4. group 4 (diabetes type 2) : 27 patients, will be receiving colostrum capsule 500 mg per oral once daily. researchers will compare groups 1,2,3, and 4 to observe the effect of the tested treatment regimens on fasting blood glucose, hba1c, lipid profile, rate pressure product, c-reactive protein, hematological indices, and body mass index. and use these measures in special formulas to determine the effect of the tested regimens on physical performance and cognitive function.


Eligibility criteria:
inclusion criteria: * apperantly healthy patients for control * patients diagnosed with t2dm * age between 18-70 exclusion criteria: * patients with t1dm * patients with a drug history of anabolic substances for more than 14 days duration. * patients with co-morbidities (e.g. cvs, renal, hepatic, and endocrine disorders) * pregnancy, lactation, or female patient willing for conception.

Keywords: colostrum diabetes mellitus, type 2 cognition physical functional performance
prediction of carotid occlusion intolerance by transcranial doppler evaluation in patients undergoing carotid artery stenting with proximal flow arrest protection system.

Conditions: Carotid Occlusion Intolerance

Summary: the aim of this observational pilot study is to determine whether intolerance of carotid occlusion during carotid artery stenting can be predicted with preprocedural transcranial doppler evaluation.

carotid artery stenting procedures are increasingly performed with devices that involve endovascular clamping of the common carotid artery, thus exposing the ipsilateral hemisphere to hypoperfusion. approximately 5% of patients do not tolerate the clamp and are in increased risk of periprocedural cerebrovascular complication such as transient ischemic attack or stroke. to date, there is no method available that could be used to predict the risk of occlusion intolerance. the aim of this study is to determine whether preprocedural evaluation with transcranial doppler ultrasonography can be effective in prediction of occlusion intolerance.

Eligibility criteria:
inclusion criteria: * either \>50% symptomatic carotid artery stenosis (transient ischemic attack or ischemic stroke within 6 months before procedure) or \>70% asymptomatic carotid artery stenosis eligible for carotid artery stenting with proximal flow arrest protection * signed informed consent exclusion criteria: * disagreement to be included in the study * inadequate acoustic window for transcranial doppler ultrasound monitoring * carotid occlusion * significant extracranial artery stenosis (\>50%) other than target artery * inability to hold breath for sufficient time (approximately 30s)

Keywords: carotid stenting proximal protection system transcranial doppler ultrasound cerebrovascular reserve
locating nociceptive stimuli on digital body chart

Conditions: Low Back Pain; Healthy Volunteers

Summary: digital body charts are used to assess the pain experience in people with pain. people are asked to report their pain by shading a human body template on a digital tablet. the aim of this study is to investigate whether people with chronic low back pain, compared to healthy volunteers, consistently locate on a digital body chart all nociceptive stimuli induced in the lumbar region.

healthy volunteers and people presenting chronic low back pain, will be recruited. a standardized grid will be drawn over the participants' lumbar region. circular electrodes, connected to a constant current stimulator, will be applied at points on the grid. all participants will be blinded to the electrode locations. painful electrocutaneous stimuli will be randomly delivered for each electrode. participants will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation. the body chart will be centred on a canvas 768x1024 pixels (pxl), and pain location will be defined by x and y coordinates. the consistency in reporting the location of each painful stimulation will be described through coordinates. in addition, only people presenting chronic low back pain will be asked to provide information about their lifestyle, level of disability, actual pain and general pain, assessment of kinesiophobia and health status.

Eligibility criteria:
inclusion criteria: * chronic low back pain (duration more than three months) exclusion criteria: * denial of informed consent; * presence of pacemaker; * pregnancy or possible pregnancy status; * lumbar surgery (spinal fusion); * documented degenerative pathology of the central nervous system; * documented concomitant pathology altering sensitivity (e.g. diabetes, fibromyalgia); * reduced motor control of the dominant hand (reported by every subject as conditioning the writing and therefore the ability to compile the body chart); * presence of skin moles and/or scars on the back that may interfere with the conduction of the electrical stimulus.

Keywords: chronic low back pain
3d printed donor tooth replica in autotransplantation of teeth

Conditions: Decayed Teeth

Summary: 3d printed replicas of the donor tooth can reduce extraoral time during the autotransplantation of teeth, which can reduce dehydration and manipulation of periodontal tissue of the donor tooth, thus possibly increasing the success rate.

this technique of autotransplantation has been innovated using 3-dimensional (3d) imaging and rapid prototyping.the use of a 3d-printed replica of the donor tooth is thought to minimize the risk of iatrogenic damage to the actual donor tooth. nevertheless, no large prospective and comparative studies are available to assess the outcomes using these 3d techniques. therefore, this study aimed to compare 3d printed replicas in autotransplantation of teeth, compared to the conventional technique. the present study will evaluate the feasibility, clinical satisfied accuracy, and stability of a novel approach for computer-aided autotransplantation of teeth. this new approach facilitated the surgical procedure and might be a viable and predictable method for autotransplantation of teeth. application of printed 3d replicas of transplanted teeth facilitates surgical preparation of the recipient site, shortens the extra-alveolar time, and reduces the minimum the number of attempts of the donor tooth insertion at the prepared socket. their use can significantly decrease the risk of damage to the root surface of a transplant, thus increasing the chance of success.

Eligibility criteria:
inclusion criteria: 1. patient presenting with decayed first molars 2. autotransplantation of third molar at the recipient site exclusion criteria: 1. diabetic, pregnant patients 2. other autotransplantations (other than first molar recipient and third molar donor)

Keywords: decayed teeth; autotransplantation; 3d printing
serum pro-diabetes inflammation biomarkers in patients with apical periodontitis.

Conditions: Apical Periodontitis; Insulin Resistance; PreDiabetes; Diabetes; Stable

Summary: inflammation is a common factor of chronic periodontitis and diabetes. however, to date, there is no scientific evidence supporting a causal effect of the inflammation created by apical periodontitis on the onset of insulin resistance and on metabolic derangement in the condition of pre-diabetes or diabetes. a case control study has been designed in order to evaluate serum levels of pro-diabetes inflammation factors in a sample of healthy patients between 25 and 55 years of age, with or without apical periodontitis,before endodontic treatment and at 6 and 12 months post-treatment. the aim of the study is to evaluate any relation between the presence of chronic endodontic lesions and pro-diabetes inflammation factors that can promote the onset of insulin resistance, and whether endodontic treatment can reduce these factors, thus preventing a pro-diabetes status.

healthy, consenting and informed patients of both gender under 55 years of age with apical periodontitis will be enrolled as cases. healthy, consenting and informed patients of both gender under 55 years of age without apical periodontitis will be enrolled as control subjects. the study has been designed to assess the serum level of tnf-α, il-1β, il-6, il-8 by elisa assay.

Eligibility criteria:
inclusion criteria: * 25-55 years, healthy exclusion criteria: * under 25 years, over 55 years, patients with systemic or oral diseases or patients who underwent other dental treatments in the previous 6 months

Keywords: endodontics apical periodontitis insulin resistance diabetes pro-diabetes inflammation markers
translational investigation of growth and everyday routines in kids

Conditions: Childhood Obesity

Summary: the purpose of this study is to determine the effect of severe obesity on physical activity, sedentary behavior and cardiometabolic risk factors during childhood and adolescence and whether these associations are modified by race. additionally, the study will investigate the contributions of (total, regional, and depot-specific) fat accumulation on changes in physical activity, sedentary behavior, and cardiometabolic risk factors during childhood and adolescence.

the proposed study will establish a prospective pediatric cohort to identify intervention targets based on the location, timing, barriers, and facilitators of current physical activity and sedentary behavior in a child's day. the project will be a prospective examination of 340 african american and white girls and boys aged 10 to 16 years, including 50% who are classified as severely obese. state-of-the-art technology will be used including accelerometry to quantify physical activity, magnetic resonance imaging to quantify fat accumulation, and geographic position system and ecological momentary assessment to identify environmental and socio-emotional barriers and facilitators. in further detail, this study will examine the following objectives: objective 1: determine the effect of severe obesity on physical activity, sedentary behavior, and cardiometabolic risk factors during childhood and adolescence and whether these associations are modified by race. objective 2: investigate the contribution of (total, regional, and depot-specific) fat accumulation on changes in physical activity, sedentary behavior, and cardiometabolic risk factors during childhood and adolescence. objective 3: determine barriers and facilitators of physical activity that are related to obesity, including environmental and socio-emotional factors.

Eligibility criteria:
inclusion criteria: * age 10-16 years * body weight \< 500 lbs. * ability to understand instructions and complete all study procedures exclusion criteria: * pregnant * on a restrictive diet due to illness * significant physical or mental disabilities that impede walking, wearing accelerometer or gps, or responding to ema.

Keywords: physical activity sedentary behavior cardiometabolic risk factors childhood and adolescence
a blinded, four-way crossover in healthy subjects to assess eeg after administration of ketamine, placebo and azd6765

Conditions: Healthy

Summary: this study will provide data to support preclinical to clinical translation by aligning preclinical and clinical efficacy assay with dose dependent changes in eeg.

a phase i, randomized, double-blind, four-way cross-over study in healthy subjects to assess quantitative electroencephalography (qeeg) parameters after the administration of ketamine, two doses of azd6765 and placebo

Eligibility criteria:
inclusion criteria: * bmi 18-30 non-smoker for at least 4 weeks exclusion criteria: * any clinically relevant acute or chronic disease * history of substance abuse hypersensitivity to ketamine

Keywords: healthy effect of a single dose on gamma-band qeeg
adipose tissue storage in the rapid remission of hepatic and cardiac metabolic dysfunction after bariatric surgery

Conditions: Diabetes Mellitus Type 2

Summary: the present protocol aims to understand and establish whether there is a causal link between adipose tissue metabolic remodeling and type 2 diabetes (t2d) remission after bariatric surgery. all participants will have a bariatric surgery, divided in 2 groups: with or without t2d.

this clinical assay will include 5 visits: the screening visit and four 9-hour postprandial metabolic sessions (a0, a1, b0 and c0) before and after surgery: * initial visit: screening * before surgery: 2 metabolic sessions a0 and a1 (without/with niacin) will be performed, in random order, at least one week interval. * 12 days post surgery: 1 metabolic session b0 (without niacin) * 1 year post surgery: 1 metabolic session c0 (without niacin) each metabolic visit will last 9 hours with: * perfusion of stable tracers, * ingestion of a liquid meal * positron-emitting-tomography (pet) acquisitions using radiopharmaceuticals such as \[18f\]-fluoro-6-thia-heptadecanoic acid (\[18f\]-ftha) and \[11c\]-palmitate, * mri acquisitions.\[18f\]fluoro-6-thia-heptadecanoic acid (ftha). the niacin will be given during metabolic visits a1 as a regulator of lipids metabolism. during these visits, the subjects will ingest 150mg every half hour for 6 hours. niacin will be used as a pharmacological suppressor of dietary fatty acid (dfa) spillover in order to determine the role played by this mechanism in the reduction of postprandial endogen glucose production (egp) in t2d after bariatric surgery.

Eligibility criteria:
inclusion criteria: * aged 18 to 65 * bmi 35 kg/m2 * diagnosed t2d - according to diabetes canada diagnostics criteria. * diagnosed non-t2d - according to diabetes canada diagnostics criteria. * women with a negative serum pregnancy test. exclusion criteria: * treatment with an oral contraceptive; * treatment with fibrate, thiazolidinedione, insulin, or beta-blocker, drugs that affect metabolism and cannot be stopped temporarily or which have long-lasting effects; * presence of overt cardiovascular disease, liver or renal failure or other uncontrolled medical conditions; * any other contraindication to surgery or to temporarily suspending current medications for diabetes, lipids or hypertension; * smoking or consumption of more than 2 alcoholic beverages per day; * any contraindication to mri; * a diabetes remission (diarem) score \>8 (low probability of t2d remission); * having participated to a research study with exposure to radiation in the last two years before the start of the study; * pregnant or breastfeeding women; * patients weighing more than 200 kg to respect the weight and gantry limit of our mri and pet/ct scanners. * being allergic to eggs

Keywords: bariatric surgery remission from type 2 diabetes pet imaging adipose tissue